Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10968825 | 0.81 | LTA4H (0.45) | MAPT | |
| SCHEMBL653251 | 0.81 | ALOX15 (0.65) | POLBALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL4947908 | 0.79 | LMNA (0.56) | POLBALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL1432953 | 0.79 | POLB (0.54) | POLBALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL12378826 | 0.79 | ALDH1A1 (0.58) | POLBALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL2531951 | 0.79 | POLB (0.54) | POLBALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL13382671 | 0.79 | POLB (0.54) | POLBALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL4946959 | 0.79 | ATF4 (0.53) | POLBALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4948856 | 0.79 | WDR5 (0.60) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL11221136 | 0.79 | NPC1 (0.53) | ALDH1A1MEN1KMT2ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1319642-B1 | Method of Preparing a Halogenated Compound | OTSUKA KAGAKU KK (JP) | 2008-03-26 | — | — | EP | disclosed |
| EP-1132391-B1 | PROCESS FOR THE PREPARATION OF 3-SULFONYLOXY-3-CEPHEM COMPOUNDS | OTSUKA KAGAKU KK (JP) | 2006-11-15 | — | — | EP | disclosed |
| EP-1447406-B1 | 3-Cephem derivative crystal | OTSUKA KAGAKU KK (JP) | 2006-08-09 | — | — | EP | disclosed |
| US-6887992-B2 | 3-cephem derivative crystal | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 2005-05-03 | — | — | US | disclosed |
| EP-1447406-A1 | 3-Cephem derivative crystal | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 2004-08-18 | — | — | EP | disclosed |
| EP-0976700-B1 | PROCESS FOR HALOGENATING HYDROXYL GROUP | OTSUKA KAGAKU KK (JP) | 2004-07-28 | — | — | EP | disclosed |
| EP-1061082-B1 | PROCESS FOR THE PREPARATION OF BETA-HYDROXY ESTERS | OTSUKA KAGAKU KK (JP) | 2004-07-14 | — | — | EP | disclosed |
| EP-1227100-B1 | 3-CEPHEM DERIVATIVE CRYSTAL AND METHOD FOR PREPARING THE SAME | OTSUKA KAGAKU KK (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-20040073023-A1 | 3-cephem derivative crystal | MORIYOSHI TAKASHI (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1209160-B1 | PROCESS FOR THE PREPARATION OF CEPHEM COMPOUNDS | OTSUKA KAGAKU KK (JP) | 2004-03-10 | — | — | EP | disclosed |
| EP-0507124-A2 | Process for preparing cephem derivatives | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1992-10-07 | — | — | EP | disclosed |
| EP-0503604-A2 | Allenyl beta-lactam compounds and process for preparing same | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1992-09-16 | — | — | EP | disclosed |
| EP-0503603-A2 | Process for preparing 2-exo-methylenepenam derivatives | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1992-09-16 | — | — | EP | disclosed |
| EP-0503597-A2 | Penam derivatives and processes for producing the same | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1992-09-16 | — | — | EP | disclosed |
| US-5142040-A | Oxidizing inpresence of oxygen with 3-halomethylcephem derivative | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1992-08-25 | — | — | US | disclosed |
| EP-0445821-A1 | Process for preparing a 3-formylcephem derivative | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1991-09-11 | — | — | EP | disclosed |
| US-4958018-A | REACTING A 3-HALOMETHYL-3-CEPHEM WITH A LEAD REDUCING AGENT | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1990-09-18 | — | — | US | disclosed |
| EP-0341694-A2 | Method for production of 3-exomethylenecepham derivatives | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1989-11-15 | — | — | EP | disclosed |
| US-4329454-A | Cephalosporin compounds | ELI LILLY AND COMPANY (US) | 1982-05-11 | — | — | US | disclosed |
| US-4144391-A | REPLACING AN ACETOXY GROUP BY A SULFUR NUCLEOPHILE | ELI LILLY AND COMPANY (US) | 1979-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073023-A1 | 3-cephem derivative crystal | CRYAA, CRYAB, PCCA | POLB 2312/4885ALDH1A1 1731/4885MEN1 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.